aRigen granted Green Cross exclusive rights to develop and commercialize injectable depsipeptide antibiotic WAP-8294A2 in Korea

aRigen Pharmaceuticals Inc.

Japan / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Green Cross Corp.

South Korea / Small-Cap Biopharma (<$1 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Terminated

Sample

01/01/2009

announced